Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
Believe Should Unwind? Look at These Scaled down Games - 2Is Iran using cryptocurrencies to circumvent sanctions?
- 3Surprising links between autism, Alzheimer’s could change how we treat both
- 420-year-old who threatened German train attack remanded in custody
- 5Taylor Swift changes 2 song lyrics on 'Reputation' on the night of her Eras tour documentary premiere
- The 15 Most Compelling Books in History
- Qatar, Ireland accuse Israel of using chemical weapons on Palestinians, demand watchdog probe use
- An Excursion Through Renowned Western Network programs
- Glamour Shots once ruled the mall. I went to one of the last ones standing.
- Ariana Grande says Eternal Sunshine 2026 tour will be her last for a 'long, long time': 'One last hurrah'
- Before Cheap Cars Were Common, This Fiat Changed Everyday Life for Millions
- An Extended time of Self-Reflection: Self-awareness through Journaling
- Find the Advantages of Careful Eating: Developing a Sound Connection with Food
- Mobility exercises are an important part of fitness as we age. Here are some tips
